Next-generation nanocarriers for precision antitumor therapy: from passive targeting to intelligent response

Dilpreet Singh , Akshay Kumar

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002355

PDF (3578KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002355 DOI: 10.37349/etat.2025.1002355
Review
research-article
Next-generation nanocarriers for precision antitumor therapy: from passive targeting to intelligent response
Author information +
History +
PDF (3578KB)

Abstract

The evolution of nanocarrier-based drug delivery systems has transformed the paradigm of cancer therapeutics, advancing from conventional cytotoxic formulations to intelligent, adaptive nanosystems capable of precision targeting. Early-generation nanocarriers exploited the enhanced permeability and retention (EPR) effect for passive tumor accumulation, yet their therapeutic efficiency remained constrained by tumor heterogeneity, limited penetration, and off-target toxicity. Emerging nanotechnologies now integrate active targeting, stimuli-responsive components, and biomimetic strategies to achieve spatiotemporal control over drug release and tumor-selective action. These “intelligent” nanocarriers are designed to recognize molecular signatures, respond dynamically to tumor microenvironmental cues such as pH, redox gradients, hypoxia, and enzymatic activity, and even engage in real-time feedback through imaging or biosensing modules. In addition, hybrid and multifunctional platforms-combining liposomes, micelles, dendrimers, polymeric nanoparticles, and inorganic systems- offer programmable functionality and synergistic delivery of chemotherapeutic, gene-editing, and immunomodulatory agents. This review delineates the mechanistic basis of passive and active targeting, highlights recent innovations in stimuli-responsive and biomimetic nanocarriers, and explores translational and regulatory perspectives shaping their clinical journey. By integrating nanotechnology with systems biology and artificial intelligence, next-generation nanocarriers promise to redefine the landscape of precision antitumor therapy.

Keywords

nanocarriers / antitumor therapy / EPR effect / active targeting / stimuli-responsive systems / biomimetic nanoparticles / tumor microenvironment / precision medicine

Cite this article

Download citation ▾
Dilpreet Singh, Akshay Kumar. Next-generation nanocarriers for precision antitumor therapy: from passive targeting to intelligent response. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002355 DOI:10.37349/etat.2025.1002355

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Sharifi M, Cho WC, Ansariesfahani A, Tarharoudi R, Malekisarvar H, Sari S, et al. An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment. Cancers (Basel). 2022; 14: 2868.

[2]

Hirsjärvi S, Passirani C, Benoit J. Passive and Active Tumour Targeting with Nanocarriers. Curr Drug Discov Technol. 2011; 8: 188-96.

[3]

Gajbhiye KR, Gajbhiye J. EPR effect based nanocarriers targeting for treatment of cancer. Int J Drug Deliv. 2017; 8: 117-24.

[4]

Meher N, Bidkar AP, Wadhwa A, Bobba KN, Dhrona S, Dasari C, et al. PET Imaging Using89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer. Mol Cancer Ther. 2025; 24: 141-51.

[5]

Akhter MH, Beg S, Tarique M, Malik A, Afaq S, Choudhry H, et al. Receptor-based targeting of engineered nanocarrier against solid tumors: Recent progress and challenges ahead. Biochim Biophys Acta Gen Subj. 2021; 1865: 129777.

[6]

Alqaraghuli H, Kashanian S, Rafipour R, Mansouri K. Dopamine-conjugated apoferritin protein nanocage for the dual-targeting delivery of epirubicin. Nanomed J. 2019; 6: 250-7.

[7]

Zhang M, Ma H, Wang X, Yu B, Cong H, Shen Y. Polysaccharide-based nanocarriers for efficient transvascular drug delivery. J Control Release. 2023; 354: 167-87.

[8]

Yang Y, Tai X, Shi K, Ruan S, Qiu Y, Zhang Z, et al. A New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor via Systemic Administration by Taking Advantages of the Limitation of EPR Effect. Theranostics. 2016; 6: 2141-60.

[9]

Hansen AE, Petersen AL, Henriksen JR, Boerresen B, Rasmussen P, Elema DR, et al. Positron Emission Tomography Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer Using Copper-64 Liposomes. ACS Nano. 2015; 9: 6985-95.

[10]

Liu X, Jiang J, Meng H. Transcytosis-An effective targeting strategy that is complementary to “EPR effect” for pancreatic cancer nano drug delivery. Theranostics. 2019; 9: 8018-25.

[11]

Bonferoni MC, Rassu G, Gavini E, Sorrenti M, Catenacci L, Torre ML, et al. Electrochemotherapy of Deep-Seated Tumors: State of Art and Perspectives as Possible “EPR Effect Enhancer” to Improve Cancer Nanomedicine Efficacy. Cancers (Basel). 2021; 13: 4437.

[12]

Ejigah V, Owoseni O, Bataille-Backer P, Ogundipe OD, Fisusi FA, Adesina SK. Approaches to Improve Macromolecule and Nanoparticle Accumulation in the Tumor Microenvironment by the Enhanced Permeability and Retention Effect. Polymers (Basel). 2022; 14: 2601.

[13]

Fan Y, Yuan S, Huo M, Chaudhuri AS, Zhao M, Wu Z, et al. Spatial controlled multistage nanocarriers through hybridization of dendrimers and gelatin nanoparticles for deep penetration and therapy into tumor tissue. Nanomedicine. 2017; 13: 1399-410.

[14]

Huang D, Sun L, Huang L, Chen Y. Nanodrug Delivery Systems Modulate Tumor Vessels to Increase the Enhanced Permeability and Retention Effect. J Pers Med. 2021; 11: 124.

[15]

Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011; 63: 131-5.

[16]

Subhan MA, Yalamarty SSK, Filipczak N, Parveen F, Torchilin VP. Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment. J Pers Med. 2021; 11: 571.

[17]

Golombek SK, May JN, Theek B, Appold L, Drude N, Kiessling F, et al. Tumor targeting via the enhanced permeability and retention (EPR) effect: strategies to enhance patient responses. Adv Drug Deliv Rev. 2018; 130: 17-38.

[18]

Chamundeeswari M, Jeslin J, Verma ML. Nanocarriers for drug delivery applications. Environ Chem Lett. 2019; 17: 849-65.

[19]

Bazak R, Houri M, Achy SE, Hussein W, Refaat T. Passive targeting of nanoparticles to cancer: A comprehensive review of the literature. Mol Clin Oncol. 2014; 2: 904-8.

[20]

Chariou PL, Ortega-Rivera OA, Steinmetz NF. Nanocarriers for the Delivery of Medical, Veterinary, and Agricultural Active Ingredients. ACS Nano. 2020; 14: 2678-701.

[21]

Dahiya S, Dahiya R, Hernández E. Nanocarriers for Anticancer Drug Targeting: Recent Trends and Challenges. Crit Rev Ther Drug Carrier Syst. 2021; 38: 49-103.

[22]

Giodini L, Re FL, Campagnol D, Marangon E, Posocco B, Dreussi E, et al. Nanocarriers in cancer clinical practice: a pharmacokinetic issue. Nanomedicine. 2017; 13: 583-99.

[23]

Cheng B. Multifunctional nanocarriers for cancer therapy [dissertation]. Columbia: University of South Carolina; 2016.

[24]

Kachore S, Chambhare N. A Comprehensive Review on the Recent Applications and Development in Nanocarriers. Asian J Pharm. 2024; 18.

[25]

Liu J, Cabral H, Mi P. Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release. Adv Drug Deliv Rev. 2024; 207: 115239.

[26]

Yang BC, Chu ZF, Zhu S, Wang LJ, Feng YH, Li FH, et al. Study of pharmacokinetics and tissue distribution of liposomal brucine for dermal administration. Int J Nanomedicine. 2011; 6: 1109-16.

[27]

Salimi A, Gobadian H, Sharif Makhmalzadeh B. Dermal pharmacokinetics of rivastigmine-loaded liposomes: an ex vivo-in vivo correlation study. J Liposome Res. 2021; 31: 246-54.

[28]

McCarley KD, Bunge AL. Pharmacokinetic models of dermal absorption. J Pharm Sci. 2001; 90: 1699-719.

[29]

Zhu Y, Wang F, Zhao Y, Zheng X. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia: a literature review of pharmaceutical and clinical aspects. Eur J Hosp Pharm. 2020; 28: 124-8.

[30]

Riegelman S. Pharmacokinetics; Pharmacokinetic factors affecting epidermal penetration and percutaneous adsorption. Clin Pharmacol Ther. 1974; 16: 873-83.

[31]

Schwarz JC, Kählig H, Matsko NB, Kratzel M, Husa M, Valenta C. Decrease of Liposomal Size and Retarding Effect on Fluconazole Skin Permeation by Lysine Derivatives. J Pharm Sci. 2011; 100: 2911-9.

[32]

Pierre MB, Dos Santos Miranda Costa I. Liposomal systems as drug delivery vehicles for dermal and transdermal applications. Arch Dermatol Res. 2011; 303: 607-21.

[33]

Voelkner NMF, Voelkner A, Derendorf H. Determination of Dermal Pharmacokinetics by Microdialysis Sampling in Rats. Curr Protoc Pharmacol. 2019; 85: e58.

[34]

Wijnant GJ, Van Bocxlaer K, Fortes Francisco A, Yardley V, Harris A, Alavijeh M, et al. Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B. Antimicrob Agents Chemother. 2018; 62: e00631-18.

[35]

Kreilgaard M. Dermal Pharmacokinetics of Microemulsion Formulations Determined by In Vivo Microdialysis. Pharm Res. 2001; 18: 367-73.

[36]

Pushp P, Kaur R, Lee HT, Gupta MK. Nanoparticles for Gene Delivery into Stem Cells and Embryos. In: Dutta P, Dutta J. Multifaceted Development and Application of Biopolymers for Biology, Biomedicine and Nanotechnology. Berlin: Springer Berlin Heidelberg; 2012. pp. 51-85.

[37]

Morachis JM, Mahmoud EA, Sankaranarayanan J, Almutairi A. Triggered rapid degradation of nanoparticles for gene delivery. J Drug Deliv. 2012; 2012: 291219.

[38]

Jin S, Leach JC, Ye K. Nanoparticle-Mediated Gene Delivery. Methods Mol Biol. 2009; 544: 547-57.

[39]

Nimesh S. Potential Implications of Nanoparticle Characterization on In Vitro and In Vivo Gene Delivery. Ther Deliv. 2012; 3: 1347-56.

[40]

Dizaj SM, Jafari S, Khosroushahi AY. A sight on the current nanoparticle-based gene delivery vectors. Nanoscale Res Lett. 2014; 9: 252.

[41]

Xu G, Zhang N. Nanoparticles for Gene Delivery: A Brief Patent Review. Recent Pat Drug Deliv Formul. 2009; 3: 125-36.

[42]

Prabu SL, Suriyaprakash TNK, Thirumurugan R. Medicated nanoparticle for gene delivery. In: Advanced Technology for Delivering Therapeutics. InTech; 2017. pp. 13-29.

[43]

Wang Y, Huang L. Composite nanoparticles for gene delivery. Adv Genet. 2014; 88: 111-37.

[44]

Shi Y, van der Meel R, Chen X, Lammers T. The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics. 2020; 10: 7921-4.

[45]

Lambert G, Fattal E, Couvreur P. Nanoparticulate systems for the delivery of antisense oligonucleotides. Adv Drug Deliv Rev. 2001; 47: 99-112.

[46]

Nakamura Y, Mochizuki A, Choyke PL, Kobayashi H. Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer? Bioconjug Chem. 2016; 27: 2225-38.

[47]

Huang SW, Zhuo R. Recent progress in polymer-based gene delivery vectors. Chin Sci Bull. 2003; 48: 1304-9.

[48]

Zhang P, Wagner E. History of Polymeric Gene Delivery Systems. Top Curr Chem (Cham). 2017; 375: 26.

[49]

Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discov. 2005; 4: 581-93.

[50]

Garnett MC. Gene-delivery systems using cationic polymers. Crit Rev Ther Drug Carrier Syst. 1999; 16: 147-207.

[51]

Wu H. Current Development of the Applications of Polymers in Gene Delivery. E3S Web Conf; 2021.

[52]

Gebhart CL, Kabanov AV. Perspectives on Polymeric Gene Delivery. J Bioact Compat Polym. 2003; 18: 147-66.

[53]

Sun Q, Stolnik S. Polymer-based gene delivery system fabricated with the participation of a polyanion. In: NSTI-Nanotech 2006. Nano Science and Technology Institute; 2006. pp. 758-61.

[54]

Anwer K, Rhee BG, Mendiratta SK. Recent Progress in Polymeric Gene Delivery Systems. Crit Rev Ther Drug Carrier Syst. 2003; 20: 249-93.

[55]

Garrec DL, Ranger M, Leroux JC. Micelles in anticancer drug delivery. Am J Drug Deliv. 2004; 2: 15-42.

[56]

Mahmud A, Xiong XB, Aliabadi HM, Lavasanifar A. Polymeric micelles for drug targeting. J Drug Target. 2007; 15: 553-84.

[57]

Torchilin VP. Lipid-Core Micelles for Targeted Drug Delivery. Curr Drug Deliv. 2005; 2: 319-27.

[58]

Aliabadi HM, Lavasanifar A. Polymeric micelles for drug delivery. Expert Opin Drug Deliv. 2006; 3: 139-62.

[59]

Mallya P, Gowda DV, Mahendran B, Bhavya MV, Jain V. Recent developments in nano micelles as drug delivery system. Int J Res Pharm Sci. 2020; 11: 176-84.

[60]

Lin TY, Li YP, Zhang H, Luo J, Goodwin N, Gao T, et al. Tumor-Targeting Multifunctional Micelles for Imaging and Chemotherapy of Advanced Bladder Cancer. Nanomedicine (Lond). 2013; 8: 1239-51.

[61]

Zhang X, Liang N, Gong X, Kawashima Y, Cui F, Sun S. Tumor-targeting micelles based on folic acid and α-tocopherol succinate conjugated hyaluronic acid for paclitaxel delivery. Colloids Surf B Biointerfaces. 2019; 177: 11-8.

[62]

Yang X, Grailer JJ, Pilla S, Steeber DA, Gong S. Tumor-Targeting, pH-Responsive, and Stable Unimolecular Micelles as Drug Nanocarriers for Targeted Cancer Therapy. Bioconjug Chem. 2010; 21: 496-504.

[63]

Durgun ME, Güngör S, Özsoy Y. Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases. J Ocul Pharmacol Ther. 2020; 36: 323-41.

[64]

Dane KY, Nembrini C, Tomei AA, Eby JK, O’Neil CP, Velluto D, et al. Nano-sized drug-loaded micelles deliver payload to lymph node immune cells and prolong allograft survival. J Control Release. 2011; 156: 154-60.

[65]

Dvir T, Bauer M, Schroeder A, Tsui JH, Anderson DG, Langer R, et al. Nanoparticles Targeting the Infarcted Heart. Nano Lett. 2011; 11: 4411-4.

[66]

Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. A Systematic Analysis of Peptide Linker Length and Liposomal Polyethylene Glycol Coating on Cellular Uptake of Peptide-Targeted Liposomes. ACS Nano. 2013; 7: 2935-47.

[67]

Anhorn MG, Wagner S, Kreuter J, Langer K, von Briesen H. Specific Targeting of HER2 Overexpressing Breast Cancer Cells with Doxorubicin-Loaded Trastuzumab-Modified Human Serum Albumin Nanoparticles. Bioconjug Chem. 2008; 19: 2321-31.

[68]

Cressman S. RGD-containing ligands for targeting liposomal nanoparticles [dissertation]. Vancouver: University of British Columbia; 2007.

[69]

Stefanick JF, Omstead DT, Kiziltepe T, Bilgicer B. Dual-receptor targeted strategy in nanoparticle design achieves tumor cell selectivity through cooperativity. Nanoscale. 2019; 11: 4414-27.

[70]

Lohiya G, Katti DS. Carboxylated chitosan-mediated improved efficacy of mesoporous silica nanoparticle-based targeted drug delivery system for breast cancer therapy. Carbohydr Polym. 2022; 277: 118822.

[71]

Zhang Y, Li S, Zhou X, Sun J, Fan X, Guan Z, et al. Construction of a Targeting Nanoparticle of 3',3”-Bis-Peptide-siRNA Conjugate/Mixed Lipid with Postinserted DSPE-PEG2000-cRGD. Mol Pharm. 2019; 16: 4920-8.

[72]

Khare P, Edgecomb SX, Hamadani CM, Tanner EEL, S Manickam D. Lipid nanoparticle-mediated drug delivery to the brain. Adv Drug Deliv Rev. 2023; 197: 114861.

[73]

Sanchez C, El Hajj Diab D, Connord V, Clerc P, Meunier E, Pipy B, et al. Targeting a G-Protein-Coupled Receptor Overexpressed in Endocrine Tumors by Magnetic Nanoparticles To Induce Cell Death. ACS Nano. 2014; 8: 1350-63.

[74]

Gary-Bobo M, Vaillant O, Maynadier M, Basile I, Gallud A, El Cheikh, et al. Targeting Multiplicity: The Key Factor for Anti-Cancer Nanoparticles. Curr Med Chem. 2013; 20: 1946-55.

[75]

Guimaraes GJ, Kim J, Bartlett MG. Characterization of mRNA therapeutics. Mass Spectrom Rev. 2024; 43: 1066-90.

[76]

Luo Z, Chen Y. Unlocking Delivery Strategies for mRNA Therapeutics. Recent Pat Anticancer Drug Discov. 2024; 19: 126-9.

[77]

Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010; 148: 135-46.

[78]

Weissman D. mRNA transcript therapy. Expert Rev Vaccines. 2015; 14: 265-81.

[79]

Rohner E, Yang R, Foo KS, Goedel A, Chien KR. Unlocking the promise of mRNA therapeutics. Nat Biotechnol. 2022; 40: 1586-600.

PDF (3578KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉